Search results
Oppenheimer cuts Spruce Biosciences shares target, cites updated revenue forecasts By Investing.com
Investing.com· 17 hours agoOn Thursday, Oppenheimer adjusted its price target for Spruce Biosciences, Inc. (NASDAQ:SPRB)...
Kiora Pharmaceuticals director buys $25,668 in company stock By Investing.com
Investing.com· 11 hours agoKiora Pharmaceuticals Inc. (NASDAQ:KPRX) director Erin Parsons (NYSE:PSN) has recently invested...
Rezolute announces public offering of common stock By Investing.com
Investing.com· 10 hours agoRezolute , Inc. (NASDAQ:RZLT), a biopharmaceutical company specializing in treatments for rare...
GameStop Analyst Lowers Price Target After 'Rambling Presentation By Roaring Kitty': Does Video Game...
Benzinga via Yahoo Finance· 2 days agoShares of video game retailer GameStop Corporation (NYSE:GME) have traded higher in recent weeks on...
Should You Buy the Dip on Compass Pathways Stock?
Motley Fool via Yahoo Finance· 2 days agoThe biotech also has enough money on its balance sheet to adjust its course to avoid the same problems. Its cash, equivalents, and short-term ...
Processa reports positive Phase 1b trial results for cancer drug By Investing.com
Investing.com· 3 days agoProcessa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage pharmaceutical company, has announced...
Maxim cuts Avenue Therapeutics shares target, highlights upcoming trial data By Investing.com
Investing.com· 7 days agoOn Friday, Maxim (NASDAQ:MXIM) Group adjusted its stance on Avenue Therapeutics (NASDAQ:ATXI)...
Immunic shareholders elect directors, ratify auditor By Investing.com
Investing.com· 17 hours agoImmunic, Inc. (NASDAQ:IMUX), a biopharmaceutical company specializing in the development of...
Merus N.V. VP controller Harry Shuman sells shares worth over $475,000 By Investing.com
Investing.com· 1 day agoIn a recent transaction, Harry Shuman, the VP Controller and Principal Accounting Officer (PAO) of...
Tevogen secures $50 million to boost R&D and IP assets By Investing.com
Investing.com· 2 days agoInc. (NASDAQ:TVGN), a biotech firm specializing in immunotherapy, announced a definitive agreement...